Factor V leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen.

被引：0
|
作者：
Garber, JE
Halabi, S
Kaplan, E
Edge, S
Dressler, L
Paskett, E
Berliner, N
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Duke Univ, Durham, NC 27706 USA
[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[4] Univ N Carolina, Chapel Hill, NC USA
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Yale Univ, Sch Med, New Haven, CT 06520 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6S / 6S
页数：1
相关论文
共 50 条
  • [1] Factor V Leiden (FVL) and prothrombin G20210A (PTG) mutations and risk of thromboembolic events (TE) in NSABP P-1, the breast cancer prevention trial (BCPT).
    Garber, JE
    Costantino, JP
    Wickerham, DL
    Berliner, N
    Wolmark, N
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S107 - S107
  • [2] Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer
    Garber, Judy E.
    Halabi, Susan
    Tolaney, Sara M.
    Kaplan, Ellen
    Archer, Laura
    Atkins, James N.
    Edge, Stephen
    Shapiro, Charles L.
    Dressler, Lynn
    Paskett, Electra M.
    Kimmick, Gretchen
    Orcutt, James
    Scalzo, Anthony
    Winer, Eric
    Levine, Ellis
    Shahab, Nasir
    Berliner, Nancy
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (13): : 942 - 949
  • [3] Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer (vol 102, pg 942, 2010)
    Garber, Judy E.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (15): : 1210 - 1210
  • [4] Arterial thromboembolic events in patients with the factor V Leiden mutation
    Eskandari, MK
    Bontempo, FA
    Hassett, AC
    Faruki, H
    Makaroun, MS
    [J]. AMERICAN JOURNAL OF SURGERY, 1998, 176 (02): : 122 - 125
  • [5] Effect of Factor v Leiden and prothrombin G20210→A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial
    Abramson, Neil
    Costantino, Joseph R.
    Garber, Judy E.
    Berliner, Nancy
    Wickerham, D. Lawrence
    Wolmark, Norman
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (13): : 904 - 910
  • [6] Thromboembolic events in Fabry disease and the impact of factor V Leiden
    Lenders, Malte
    Karabul, Nesrin
    Duning, Thomas
    Schmitz, Boris
    Schelleckes, Michael
    Mesters, Rolf
    Hense, Hans-Werner
    Beck, Michael
    Brand, Stefan-Martin
    Brand, Eva
    [J]. NEUROLOGY, 2015, 84 (10) : 1009 - 1016
  • [7] Thromboembolic events in Fabry disease and the impact of factor V Leiden
    Lenders, Malte
    Karabul, Nesrin
    Duning, Thomas
    Schmitz, Boris
    Schelleckes, Michael
    Mesters, Rolf
    Hense, Hans-Werner
    Beck, Michael
    Brand, Stefan-Martin
    Brand, Eva
    [J]. MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S71 - S72
  • [8] Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen
    McCaskill-Stevens, W
    Wilson, J
    Bryant, J
    Mamounas, E
    Garvey, L
    James, J
    Cronin, W
    Wickerham, DL
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (23): : 1762 - 1769
  • [9] ADJUVANT TAMOXIFEN IN BREAST-CANCER-TREATMENT IN POSTMENOPAUSAL WOMEN - OCCURRENCE OF THROMBOEMBOLIC COMPLICATIONS
    CUTULI, BF
    PETIT, JC
    FRICKER, JP
    JUNG, GM
    SCHUMACHER, C
    VELTEN, M
    ABECASSIS, J
    [J]. ONCOLOGY REPORTS, 1994, 1 (01) : 59 - 63
  • [10] The association between Factor V Leiden and thromboembolic events in autopsy patients
    Sanders, ME
    Soltys, S
    Litzky, LA
    Leonard, DGB
    [J]. MODERN PATHOLOGY, 1998, 11 (01) : 6A - 6A
12345